We speak to Dr. Elena Castro about the latest data on PARP inhibitors in prostate cancer as presented at this year's ASCO Genitourinary Cancers Symposium.
Prof. Chantal Mathieu explains the progress being made with disease-modifying therapy for type 1 diabetes and how it has the potential to transform the current treatment landscape.
Prof. Marion Subklewe explores the interplay between the gut microbiota and the efficacy and safety of CAR T-cell therapy in people with hematologic malignancies.